Please wait
POS AM EX-FILING FEES 0001828805 333-273149 true true true true true N/A N/A 0001828805 1 2026-02-03 2026-02-03 0001828805 2 2026-02-03 2026-02-03 0001828805 3 2026-02-03 2026-02-03 0001828805 4 2026-02-03 2026-02-03 0001828805 5 2026-02-03 2026-02-03 0001828805 2026-02-03 2026-02-03 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-3

Aeluma, Inc.

Table 3: Combined Prospectuses

                               
Security Type   Security Class Title   Notes   Amount of Securities Previously Registered   Maximum
Aggregate Offering
Price of
Securities Previously Registered		   Form Type   File Number   Initial Effective Date
                               
Equity   Common Stock   (1)   10,650,002    $ 21,300,004.00   S-1   333-259179   01/19/2022
Equity   Common Stock issuable upon exercise of 2021 Placement Agent Warrants   (2)   360,000      720,000.00   S-1   333-259179   01/19/2022
Equity   Common Stock   (3)   2,017,498      6,052,500.00   S-1   333-273149   09/28/2023
Equity   Common Stock issuable upon exercise of the 2023 Placement Agent Warrants   (4)   85,653      256,959.00   S-1   333-273149   09/28/2023
Equity   Common Stock underlying Convertible Notes   (5)   898,573      3,145,005.50   S-1   333-285469   03/25/2025

__________________________________________
Prospectus Note(s):

(1) In accordance with Rule 416(a), the Registrant is also registering an indeterminate number of additional shares of ordinary shares that shall be issuable pursuant to Rule 416 to prevent dilution resulting from share splits, share dividends or similar transactions.

Consists of (i) 4,000,000 shares of our common stock issued in a private placement offering during the three months ended September 30, 2021 (the “2021 Offering), (ii) 50,000 shares issued to the placement agent in the 2021 Offering, (iii) 4,100,002 shares of our common stock issued as a result of the conversion of shares of Biond Photonics, Inc. (“Biond”) shares into shares of common stock in connection with the merger between Biond and the Company (the “Merger”), and (iv) 2,500,000 shares of our common stock held by the Company’s stockholders prior to the Merger.
(2) In accordance with Rule 416(a), the Registrant is also registering an indeterminate number of additional shares of ordinary shares that shall be issuable pursuant to Rule 416 to prevent dilution resulting from share splits, share dividends or similar transactions.

Consists of the 360,000 shares of common stock issuable upon the exercise of the placement agent warrants issued in connection with the 2021 Offering.
(3) In accordance with Rule 416(a), the Registrant is also registering an indeterminate number of additional shares of ordinary shares that shall be issuable pursuant to Rule 416 to prevent dilution resulting from share splits, share dividends or similar transactions.

Consists of 2,017,498 shares of common stock issued in a private placement offering that occurred between December of 2022 and May 2023 (the “2023 Offering”).
(4) In accordance with Rule 416(a), the Registrant is also registering an indeterminate number of additional shares of ordinary shares that shall be issuable pursuant to Rule 416 to prevent dilution resulting from share splits, share dividends or similar transactions.

Consists of the 85,653 shares of common stock issuable upon the exercise of the placement agent warrants issued in connection with the 2021 Offering.
(5) In accordance with Rule 416(a), the Registrant is also registering an indeterminate number of additional shares of ordinary shares that shall be issuable pursuant to Rule 416 to prevent dilution resulting from share splits, share dividends or similar transactions.

Reflects the 898,573 shares of common stock underlying the notes issued in private placement transactions in 2024.